{
    "clinical_study": {
        "@rank": "168182", 
        "arm_group": [
            {
                "arm_group_label": "Baricitinib + Ketoconazole", 
                "arm_group_type": "Experimental", 
                "description": "Baricitinib - 10 mg administered orally once a day (QD) on Day 1 of Period 1 and on Day 6 of Period 2.\nKetoconazole - 400 mg administered orally QD for 6 days (Days 3-8) in Period 2."
            }, 
            {
                "arm_group_label": "Baricitinib + Fluconazole", 
                "arm_group_type": "Experimental", 
                "description": "Baricitinib - 10 mg administered orally once on Day 1 of Period 1 and on Day 7 of Period 2.\nFluconazole - 400 mg administered orally once on Day 3 of Period 2, followed by 200 mg administered orally QD for 6 days (Days 4-9) in Period 2."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to look at the effect of ketoconazole and fluconazole on\n      how much baricitinib gets into the blood stream.  The study will also look at the\n      tolerability of baricitinib and ketoconazole when given together and the tolerability of\n      baricitinib and fluconazole when given together.\n\n      Participants will be recruited into one of 2 treatment groups (Group A, Group B).  Each\n      treatment group will participate in 2 study periods.  Participants will take baricitinib\n      alone in one period and baricitinib with either ketaconazole or fluconazole in the other\n      period.  This study will last approximately 7 weeks."
        }, 
        "brief_title": "A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy as determined by medical history and physical examination\n\n          -  Female participants not of childbearing potential due to surgical sterilization (at\n             least 3 months after surgical hysterectomy, bilateral oophorectomy with or without\n             hysterectomy, or bilateral tubal occlusion/ligation) confirmed by medical history or\n             menopause\n\n          -  Have a body mass index of 18 to 29 kilograms per square meter (kg/m^2), inclusive, at\n             screening\n\n        Exclusion Criteria:\n\n          -  Participants who have previously completed or withdrawn from this study or any other\n             study investigating baricitinib, and have previously received the study drug\n\n          -  Have known allergies to baricitinib, ketoconazole, fluconazole, related compounds, or\n             any components of the baricitinib, ketoconazole, or fluconazole formulations, or\n             history of significant atopy\n\n          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,\n             gastrointestinal, endocrine, hematological, or neurological disorders capable of\n             significantly altering the absorption, metabolism, or elimination of drugs; of\n             constituting a risk when taking the study medication; or of interfering with the\n             interpretation of data\n\n          -  Have a current or recent history (less than 30 days prior to screening and/or less\n             than 45 days prior to day of admission to clinical research unit) of a clinically\n             significant bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or\n             mycobacterial infection\n\n          -  Have alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline\n             phosphatase, total bilirubin, or gamma glutamyl transferase (GGT) values above the\n             upper limit of the reference range for the local laboratory at screening or day of\n             admission to clinical research unit\n\n          -  Have an absolute neutrophil count (ANC) less than 2 times 10^9 per liter (L) (2000\n             cells per microliter [\u03bcL]) at screening or day of admission to clinical research\n             unit. For abnormal values, a single repeat will be allowed\n\n          -  Intend to use over-the-counter or prescription medication and/or herbal supplements\n             within 14 days prior to dosing and during the study (with the exception of occasional\n             paracetamol, which will be permitted at the discretion of the investigator), or\n             intended use of vitamin supplements from Day 1 until discharge from the Clinical\n             Research Unit (CRU)\n\n          -  Have used or intend to use any drugs or substances that are known to be substrates,\n             inhibitors, or inducers of cytochrome P450 (CYP) 3A4, CYP2C9, or CYP2C19 within 30\n             days prior to dosing and throughout the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01924299", 
            "org_study_id": "14607", 
            "secondary_id": "I4V-MC-JAGJ"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Baricitinib + Ketoconazole", 
                    "Baricitinib + Fluconazole"
                ], 
                "description": "Administered orally", 
                "intervention_name": "Baricitinib", 
                "intervention_type": "Drug", 
                "other_name": "LY3009104"
            }, 
            {
                "arm_group_label": "Baricitinib + Ketoconazole", 
                "description": "Administered orally", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Baricitinib + Fluconazole", 
                "description": "Administered orally", 
                "intervention_name": "Fluconazole", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fluconazole", 
                "Ketoconazole"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Leeds", 
                    "country": "United Kingdom", 
                    "state": "West Yorkshire", 
                    "zip": "LS2 9LH"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effect of Ketoconazole or Fluconazole on the Pharmacokinetics of Baricitinib in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics (PK): Maximum concentration (Cmax) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Predose of baricitinib on Day 1 up to 48 hours postdose in Period 1 and Predose of baricitinib on Day 6 or 7 up to 72 hours postdose in Period 2"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (tmax) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Predose of baricitinib on Day 1 up to 48 hours postdose in Period 1 and Predose of baricitinib on Day 6 or 7 up to 72 hours postdose in Period 2"
            }, 
            {
                "measure": "Pharmacokinetics, Area Under the Plasma Concentration-Time Curve From Time 0 Hour (h) to Infinity (AUC0-\u221e) of Baricitinib", 
                "safety_issue": "No", 
                "time_frame": "Predose of baricitinib on Day 1 up to 48 hours postdose in Period 1 and Predose of baricitinib on Day 6 or 7 up to 72 hours postdose in Period 2"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01924299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}